Arcadia Biosciences (RKDA) 10-Q 8 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	RKDA
Entity Registrant Name	ARCADIA BIOSCIENCES, INC.
Entity Central Index Key	0001469443
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		4,777,419
Entity Emerging Growth Company	true
Entity Small Business	true
Extended Transition Period	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 10,438	$ 11,998
Short-term investments	7,355	9,825
Accounts receivable	79	165
Unbilled revenue		3
Inventories — current	187	181
Prepaid expenses and other current assets	506	704
Total current assets	18,565	22,876
Property and equipment, net	460	395
Right of use asset	2,193
Inventories — noncurrent	701	746
Other noncurrent assets	31	7
Total assets	21,950	24,024
Current liabilities:
Accounts payable and accrued expenses	2,062	2,645
Amounts due to related parties	12	29
Unearned revenue — current	56	96
Operating lease liability — current	574
Other current liabilities	264	284
Total current liabilities	2,968	3,054
Operating lease liability — noncurrent	1,771
Common stock warrant liabilities	13,578	5,083
Other noncurrent liabilities	3,000	3,072
Total liabilities	21,317	11,209
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 4,777,419 and 4,774,919 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	45	45
Additional paid-in capital	191,566	191,136
Accumulated deficit	(190,978)	(178,366)
Total stockholders’ equity	633	12,815
Total liabilities and stockholders’ equity	$ 21,950	$ 24,024

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	4,777,419	4,774,919
Common stock, outstanding	4,777,419	4,774,919

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Total revenues	$ 158	$ 214
Operating expenses:
Research and development	1,505	1,396
Selling, general and administrative	2,812	2,621
Total operating expenses	4,376	4,053
Loss from operations	(4,218)	(3,839)
Other income, net	120	38
Initial loss on common stock warrant and common stock adjustment feature liabilities		(4,000)
Change in fair value of common stock warrant and common stock adjustment feature liabilities	(8,495)	(1,900)
Offering costs		(904)
Net loss before income taxes	(12,593)	(10,605)
Income tax provision	(19)	(10)
Net loss	$ (12,612)	$ (10,615)
Net loss per share:
Basic and diluted	$ (2.64)	$ (4.86)
Weighted-average number of shares used in per share calculations:
Basic and diluted	4,776,540	2,186,196
Other comprehensive loss, net of tax
Unrealized losses on available-for-sale securities		$ 1
Other comprehensive loss		1
Comprehensive loss	$ (12,612)	(10,614)
Product
Revenues:
Total revenues	107	61
Operating expenses:
Cost of product revenues	59	36
Contract Research And Government Grants
Revenues:
Total revenues	$ 51	$ 153

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	June Offering [Member]	June Purchase Agreement [Member]	Common Stock [Member]	Common Stock [Member]Securities Purchase Agreement [Member]	Common Stock [Member]June Purchase Agreement [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]June Offering [Member]	Additional Paid-In Capital [Member]Securities Purchase Agreement [Member]	Additional Paid-In Capital [Member]June Purchase Agreement [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2017	$ 8,007			$ 42			$ 175,223				$ (167,257)	$ (1)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2017				2,134,153
Impact of adoption of Topic 606 | Topic 606 [Member]	2,371										2,371
Issuance of shares related to employee stock option exercises	963						963
Issuance of shares related to employee stock option exercises, Shares				44,354
Issuance of shares related to employee stock purchase plan	6						6
Issuance of shares related to employee stock purchase plan, Shares				1,122
Issuance of shares			$ 4,978		$ 1	$ 2			$ (1)	$ 4,976
Issuance of shares, Shares					1,201,634	1,392,345
Issuance of placement agent warrants	526	$ 427					526	$ 427
Common stock adjustment feature	8,378						8,378
Offering costs related to June Offering			$ (912)							$ (912)
Stock-based compensation	1,550						1,550
Issuance of shares related to reverse stock split, Shares				1,311
Other comprehensive income	1											$ 1
Net loss	(13,480)										(13,480)
Stockholders Equity, Ending Balance at Dec. 31, 2018	12,815			$ 45			191,136				(178,366)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2018				4,774,919
Issuance of shares related to employee stock purchase plan	8						8
Issuance of shares related to employee stock purchase plan, Shares				2,500
Stock-based compensation	422						422
Net loss	(12,612)										(12,612)
Stockholders Equity, Ending Balance at Mar. 31, 2019	$ 633			$ 45			$ 191,566				$ (190,978)
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2019				4,777,419

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,612)	$ (10,615)
Adjustments to reconcile net loss to cash used in operating activities:
Initial loss on common stock warrant and common stock adjustment feature liabilities		4,000
Change in fair value of common stock warrant and common stock adjustment feature liabilities	8,495	1,900
Offering costs		904
Depreciation and amortization	34	52
Lease amortization	172
Gain on disposal of equipment		(3)
Net amortization of investment premium	(39)	(2)
Stock-based compensation	422	298
Changes in operating assets and liabilities:
Accounts receivable	86	1,179
Unbilled revenue	3	(45)
Inventories	39	21
Prepaid expenses and other current assets	197	137
Accounts payable and accrued expenses	(538)	(322)
Amounts due to related parties	(16)	(25)
Unearned revenue	(40)	(96)
Operating lease payments	(172)
Net cash used in operating activities	(3,969)	(2,617)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment		9
Purchases of property and equipment	(88)	(33)
Purchases of investments	(6,690)
Proceeds from sales and maturities of investments	9,200	3,900
Net cash provided by investing activities	2,422	3,876
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Purchase Agreement		10,000
Payments of offering costs relating to Purchase Agreement		(932)
Payments of offering costs relating to June Offering	(16)
Payments of deferred offering costs	(5)
Proceeds from exercise of stock options and ESPP purchases	8	966
Net cash (used in) provided by financing activities	(13)	10,034
Net (decrease) increase in cash and cash equivalents	(1,560)	11,293
Cash and cash equivalents — beginning of period	11,998	9,125
Cash and cash equivalents — end of period	10,438	20,418
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	2	24
NONCASH INVESTING AND FINANCING ACTIVITIES:
Offering costs in accounts payable and accrued expenses at end of period	7	334
Deferred offering costs in accounts payable and accrued expenses at end of period	18
Common stock warrants issued to placement agent and included in offering costs related to Purchase Agreement		526
Right of use assets obtained in exchange for new operating lease liabilities	2,328
Proceeds from sale of fixed assets included in prepaid expenses and other current assets at end of period		$ 1
Purchases of fixed assets included in accounts payable and accrued expenses	$ 13

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015. We are a consumer-driven, agricultural food ingredient company and proven leader in agricultural innovation to improve the quality and nutritional content of crops. We aim to create value across the agricultural production and supply chain beginning with enhanced crop productivity for farmers and ultimately delivering accelerated innovation in nutritional quality consumer foods. We use state of the art gene-editing technology and advanced breeding techniques to naturally enhance the nutritional quality of grains and oilseeds to address the rapidly evolving trends in consumer health and nutrition. In addition, we have developed high value crop productivity traits designed to enhance farm economics. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 5), which is jointly owned with Bioceres Crop Solutions Corp. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca , Reverse Stock Split In January 2018, the Company’s board of directors and its shareholders approved a reverse split of 1:20 on the Company’s issued and outstanding common stock which became effective on January 23, 2018. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented. The reverse stock split did not change the total number of authorized shares of common stock which remained at one hundred and fifty million shares. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and Verdeca in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities (“VIEs”). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. The Company evaluates its relationships with the VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Interim results are not necessarily indicative of results for any other interim period or for the full fiscal year. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K, filed with the SEC on April 1, 2019. Liquidity, Capital Resources, and Going Concern As of March 31, 2019, the Company had an accumulated deficit of $191.0 million, cash and cash equivalents of $10.4 million and short-term investments of $7.4 million. For the three months ended March 31, 2019 and the twelve months ended December 31, 2018, the Company had net losses of $12.6 and $13.5 million, and net cash used in operations of $4.0 million and $13.6 million, respectively. The Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through March 2020, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2019
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement The Company is currently evaluating the impact of the adoption of ASU No. 2018-13 on its consolidated financial statements.

SONOVA Gamma Linolenic Acid ("G

SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory	3. SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil Inventory Raw materials costs consist primarily of seed production costs incurred by the Company’s contracted cooperators. Finished goods inventories consist of GLA oil that is available for sale. Inventories consist of the following (in thousands): March 31, 2019 December 31, 2018 Raw materials $ 41 $ 41 Finished goods 847 886 Inventories $ 888 $ 927

Investments and Fair Value of F

Investments and Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2019
Investments And Fair Value Of Financial Instruments [Abstract]
Investments and Fair Value of Financial Instruments	4. Investments and Fair Value of Financial Instruments Available-for-Sale Investments The Company classified short-term investments as “available-for-sale.” These short-term investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss, which is reflected as a separate component of stockholder’s equity in the Consolidated Balance Sheets. Gains and losses are recognized when realized in the Consolidated Statements of Operations and Comprehensive Loss. The following tables summarize the amortized cost and fair value of the available-for-sale investment securities portfolio at March 31, 2019 and December 31, 2018, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value March 31, 2019 Cash equivalents: Money market funds $ 6,283 $ — $ — $ 6,283 Corporate securities 599 — — 599 Commercial paper 3,044 — — 3,044 Short-term investments: Corporate securities 1,248 — — 1,248 Treasury Bills 997 — — 997 Commercial paper 5,110 — — 5,110 Total Assets at Fair Value $ 17,281 $ — $ — $ 17,281 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2018 Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper 1,345 — — 1,345 Short-term investments: Corporate Securities 656 — — 656 Treasury Bills 1,195 — — 1,195 Commercial paper 6,776 — — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 21,072 $ — $ — $ 21,072 The Company did not have any investment categories that were in a continuous unrealized loss position for more than three months as of March 31, 2019. Unrealized gains and losses amounts would be included in accumulated other comprehensive income or loss; however, none were reported during the periods presented. As of March 31, 2019, for fixed income securities that were in unrealized loss positions, the Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company anticipates that it will recover the entire amortized cost basis of such fixed income securities and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the three months ended March 31, 2019. Fair Value Measurement Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The following table sets forth the fair value of the Company’s financial assets as of March 31, 2019 and December 31, 2018: Fair Value Measurements at March 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,283 $ — $ — $ 6,283 Corporate securities — 599 — 599 Commercial paper — 3,044 — 3,044 Short-term investments: Corporate securities — 1,248 — 1,248 Treasury Bills 997 — — 997 Commercial paper — 5,110 — 5,110 Total Assets at Fair Value $ 7,280 $ 10,001 $ — $ 17,281 Fair Value Measurements at December 31, 2018 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper — 1,345 — 1,345 Short-term investments: Corporate Securities — 656 — 656 Treasury Bills 1,195 — — 1,195 Commercial paper — 6,776 — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 12,295 $ 8,777 $ — $ 21,072 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2019 or 2018. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, short-term investments and accounts payable and accrued liabilities. For accounts receivable, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of March 31, 2019 and December 31, 2018 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities, which were measured and recorded on a recurring basis, consist of liabilities related to the March 2018 Purchase Agreement and the June 2018 Offering described in Note 8. The following table sets forth the establishment of these liabilities, as well as a summary of the changes in the fair value (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - Purchase Agreement Common Stock Warrant Liability - June Offering Total Balance as of December 31, 2018 $ 2,354 $ 2,729 $ 5,083 Change in fair value 3,970 4,525 8,495 Balance as of March 31, 2019 $ 6,324 $ 7,254 $ 13,578 In determining the fair value, the Company uses various valuation approaches within the fair value measurement framework. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below: • Money market funds, treasury bills, and U.S. government securities – Investments in money market funds, treasury bills, and U.S. government securities are classified within Level 1. At March 31, 2019 and December 31, 2018 these investments were included on the consolidated balance sheets in cash and cash equivalents and short-term investments. • Commercial paper, corporate securities – Investments in commercial paper and corporate securities are classified within Level 2. At March 31, 2019 these investments were included on the consolidated balance sheets in cash and cash equivalents and short-term investments. At December 31, 2018, commercial paper was included on the consolidated balance sheets in short-term investments. • Purchase Agreement common stock warrant liability – The Company has outstanding warrants to purchase 1,282,832 shares of common stock that it issued to certain accredited investors and its placement agent on March 22, 2018 (as described in Note 8). The common stock warrants were classified as a liability within Level 3 based on the instrument’s adjustment features and a contingent cash payment feature . The estimated fair value of the common stock warrant liability was remeasured at March 31, 2019 utilizing a Black Scholes Merton Model with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss. • June 2018 Offering common stock warrant liability – The Company has outstanding warrants to purchase 1,461,962 shares of common stock that it issued to certain accredited investors on June 14, 2018 (as described in Note 8). The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature . The estimated fair value of the common stock warrant liability was remeasured at March 31, 2019 utilizing a Black Scholes Merton Model with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss.

Variable Interest Entity

Variable Interest Entity	3 Months Ended
	Mar. 31, 2019
Equity Method Investments And Joint Ventures [Abstract]
Variable Interest Entity	5. Variable Interest Entity In February 2012, the Company formed Verdeca LLC (“Verdeca”), which is equally owned with Bioceres Crop Solutions Corp. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative owned by approximately 300 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. The Company determined that a de facto agency relationship between the Company and Bioceres exists. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca. Both the Company and Bioceres incur expenses in support of specific activities, as agreed upon by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amounts of $243,000 and $ 286,000

Collaborative Arrangements

Collaborative Arrangements	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangements	6. Collaborative Arrangements In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Dow AgroSciences, LLC (“Dow”) and involves a joint operating activity where both Arcadia and Dow are active participants in the activities of the collaboration. Arcadia and Dow participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Dow will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Lessee Disclosure [Abstract]
Leases	7. Leases As of March 31, 2019, the Company leases office space in Davis, CA and Phoenix, AZ, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis. The Company subleases a portion of the Davis office lease and Greenhouse to third parties. The Company does not currently have any finance leases or material leases that have not yet commenced but that create significant rights and obligations for the Company. Some leases (the warehouse, greenhouse and the Phoenix copier) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification March 31, 2019 Assets Operating lease assets Right of use asset $ 2,193 Total leased assets $ 2,193 Liabilities Current - Operating Operating lease liability-current $ 574 Noncurrent - Operating Operating lease liability-noncurrent 1,771 Total leased liabilities $ 2,345 Lease Cost Classification For the Three Months Ended March 31, 2019 Operating lease cost SG&A and R&D Expenses $ 175 Short term lease cost(1) R&D Expenses 48 Sublease income(2) SG&A and R&D Expenses (15 ) Net lease cost $ 208 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a credit to lease expense. Lease Term and Discount Rate For the Three Months Ended March 31, 2019 Weighted-average remaining lease term (years) 2.6 Weighted-average discount rate 7%

Private Placement and Register

Private Placement and Registered Direct Offering	3 Months Ended
	Mar. 31, 2019
Warrants And Rights Note Disclosure [Abstract]
Private Placement and Registered Direct Offering Disclosure	8. Private Placement and Registered Direct Offering Private Placement On March 22, 2018, the Company issued 300,752 shares of its common stock (“Common Stock”) and warrants to purchase up to 300,752 shares of Common Stock with an initial exercise price equal to $45.75 (the “March 2018 Warrants”), in a private placement (the “March 2018 Private Placement”) in accordance with a securities purchase agreement (the “the March 2018 Purchase Agreement”) entered into with certain institutional and accredited investors (collectively, the “Purchasers”) on March 19, 2018. The number of shares of Common Stock, the number and exercise price of the March 2018 Warrants issued to the Purchasers were subject to adjustments as provided in the March 2018 Purchase Agreement. The March 2018 Warrants are immediately exercisable, subject to certain ownership limitations, and expire five years after the date of issuance. Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the Purchasers was 1,201,636, the total number of shares issuable upon exercise of the March 2018 Warrants was 1,282,832 and the per share exercise price of the March 2018 Warrants was $10.7258. These condensed consolidated financial statements reflect these additional issuances. The aggregate net proceeds received by the Company from the March 2018 Private Placement was $8.7 million, consisting of gross proceeds of $10.0 million less offering costs of $1.3 million. The Company entered into the March 2018 Private Placement to secure additional capital to strengthen its cash resources required to launch its new health and nutrition ingredient product commercialization and production scale-up plans, as well as to continue the deregulation and commercialization of its stress tolerant HB4 soybean trait. More specifically, net proceeds have been and will continue to be used for working capital to fund the continued introgression of quality ingredient traits into elite germ plasm, additional seed bulk-up, increased planting acreage, consumer brand development and a number of other pre-commercialization and commercialization activities. The adjustment feature for the Common Stock and the March 2018 Warrants were determined to be liabilities based on each instrument’s adjustment features and the contingent cash payment feature of the common stock warrants. The liabilities were accounted for at their respective fair values at inception using a Monte Carlo simulation model with the following assumptions: volatility of 100 percent, stock price of $32.52 and risk-free rate of 2.63%. At inception, the fair values of the Common Stock adjustment feature and the March 2018 Warrant liabilities were $3.8 million and $10.2 million, respectively. As the combined value of the liabilities exceeded the $10.0 million of proceeds, no value was assigned to the Common Stock issued and an initial loss of $4.0 million was recognized. The liabilities are marked-to-market and were valued at $15.9 million at March 31, 2018, resulting in an additional loss of $1.9 million in the first quarter of 2018. In May 2018, following the March 2018 Private Placement’s final adjustment, the terms of the March 2018 Warrants and the number of Common Stock shares issuable in the March 2018 Private Placement became known and fixed. As a result, the common stock adjustment feature liability was marked-to-market and valued at $8.4 million at May 7, 2018, resulting in an additional loss of $2.4 million recognized in the second quarter of 2018. The Company subsequently reclassified the Common Stock adjustment feature liability’s balance of $8.4 million to stockholders’ equity. The March 2018 Warrant liability was marked-to-market and valued at $6.3 million at March 31, 2019, resulting in expense of $4.0 million recognized in the first quarter of 2019 as the contingent cash payment feature was still in effect. Offering Costs In connection with the March 2018 Private Placement, the Company paid to a placement agent an aggregate fee equal to $850,000. The Company also granted warrants to purchase a total of 15,038 shares of common stock (the “March 2018 Placement Agent Warrants”) that have an exercise price per share equal to $41.5625 and a term of five years. The March 2018 Placement Agent Warrants were issued for services performed by the placement agent as part of the March 2018 Private Placement and were treated as offering costs. The value of the March 2018 Placement Agent Warrants was determined to be $526,000 using the Black-Scholes Merton Model (the “Black-Scholes Model”) with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $458,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the March 2018 Private Placement. The offering costs, inclusive of the March 2018 Placement Agent Warrants, totaled $1.8 million, all of which was expensed in 2018. Registered Direct Offering On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018. This registration statement allows the Company to sell any combination of Common Stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having an aggregate initial offering price of $50 million. On June 11, 2018, the Company entered into agreements with several institutional and accredited investors (the “June 2018 Purchase Agreement”) for the purchase of 1,392,345 shares of its common stock at a purchase price of $9.93 per share for gross proceeds of $13.8 million (the “June 2018 Offering”). The 1,392,345 shares of Common Stock sold in the June 2018 Offering were issued pursuant to a prospectus, dated June 8, 2018, and a prospectus supplement dated June 11, 2018, in connection with a takedown from the Company’s shelf Registration Statement on Form S-3. The June 2018 Offering closed on June 14, 2018 Additionally, in a concurrent private placement (the “June 2018 Private Placement”), the Company issued to the investors unregistered warrants to purchase up to 1,392,345 shares of Common Stock at a purchase price per warrant of $0.125, for gross proceeds of $174,000 (the “June 2018 Warrants”). The June 2018 Warrants, and the shares of Common Stock underlying the June 2018 warrants, have not been registered with the SEC and have an exercise price of $9.94 per share. Subject to certain ownership limitations, the June 2018 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance. The aggregate net proceeds received by the Company for the June 2018 Offering were $12.8 million, consisting of gross proceeds of $14.0 million less offering costs of $1.2 million. The Company has used and intends to continue to use the net proceeds from this offering for general corporate purposes, including, but not limited to, scale-up of its GoodWheat TM The June 2018 Warrants June 2018 Warrants June 2018 Warrants Offering Costs In connection with the June 2018 Offering, the Company paid to a placement agent an aggregate fee equal to $980,000. The Company also granted warrants to purchase a total of 69,617 shares of common stock (“June 2018 Placement Agent Warrants”) that have an exercise price per share equal to $12.568 and a term of five years. The June 2018 Placement Agent Warrants were issued for services performed by the placement agent as part of the June 2018 Offering and were treated as offering costs. The value of the June 2018 Placement Agent Warrants was determined to be $427,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $226,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the June 2018 Offering. The offering costs, inclusive of the June 2018 Placement Agent Warrants, totaled $1.6 million and allocated to the June 2018 Warrants and the Common Stock using their relative fair values. A total of $721,000 was allocated to the June 2018 Warrants which was expensed in 2018. The remaining $912,000 was allocated to the common stock and offset to additional paid in capital.

Stock-Based Compensation and Wa

Stock-Based Compensation and Warrants	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Share Based Payments And Warrants [Abstract]
Stock-Based Compensation and Warrants	9. Stock-Based Compensation and Warrants Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when the 2006 Plan was terminated as to future awards. The 2006 Plan continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. Options granted generally vest over a four-year period, with 25% vesting at the end of one year and the remaining vesting monthly thereafter; however, the options granted in the third quarter of 2018 vest over a two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years after grant. As of March 31, 2019, a total of 538,953 shares of common stock were reserved for issuance under the 2015 Plan, of which 65,872 shares of common stock are available for future grant. As of March 31, 2019, a total of 62,162 and 473,081 options are outstanding under the 2006 and 2015 Plans, respectively. A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2018 530,044 $ 35.53 $ — Options granted 7,500 3.57 Options exercised — — Options forfeited (1,287 ) 4.33 Options expired (1,014 ) $ 24.78 Outstanding — Balance at March 31, 2019 535,243 $ 35.13 $ 637 Vested and expected to vest — March 31, 2019 526,131 $ 35.47 $ 623 Exercisable —March 31, 2019 231,086 $ 60.40 $ 182 As of March 31, 2019, there was $0.9 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 1.9 years. The fair value of stock option awards to executives and other service providers was estimated at the date of grant using the Black-Scholes Model with the following weighted-average assumption. There were 7,500 and 10,000 options granted during the three months ended March 31, 2019 and 2018, respectively. Three Months Ended March 31, 2019 2018 Expected term (years) 2.58 6.25 Expected volatility 133 % 100 % Risk-free interest rate 2.55 % 2.73 % Dividend yield — — Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of March 31, 2019, the number of shares of common stock reserved for future issuance under the ESPP is 108,864. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of March 31, 2019, 9,353 shares had been issued under the ESPP. The Company recorded $4,300 and $ 1,200 Warrants As of March 2019, the Company has 2,821,144 common stock warrants outstanding with a weighted average exercise price of $18.15. The expiration of the warrants ranges from April 2019 to June 2023. On December 2013, the Company issued warrants to Mahyco International to purchase 3,784 shares of common stock, exercisable as of the issuance date, at an exercise price of $330.40 per share. These warrants expired on December 11, 2018. In connection with the Series D preferred stock financing in the first half of 2014, the Company issued warrants, exercisable as of the issuance date, to the Series D preferred stock investors to purchase an aggregate of 61,397 shares of common stock at an exercise price of $363.20 per share and to the placement agents to purchase 1,674 shares of common stock at $268.80. Of the 61,397 warrants issued to the investors, 1,759 expired on March 28, 2019 and the remaining 59,638 expire in the second quarter of 2019, along with those issued to the placement agents. As of March 2019, 1,297,870 common stock warrants are outstanding that were issued in the March 2018 Private Placement. The final exercise price for these warrants is $10.7258 as adjusted in accordance with the March 2018 Purchase Agreement’s adjustment provisions. See Note 8. As of March 2019, 1,461,962 common stock warrants are outstanding in accordance with the June 2018 Offering. Of the total, 1,392,345 shares have a purchase price of $9.94 and the remaining 69,617 common stock warrants have an exercise price of $12.568. See Note 8.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes. The interim financial statement provision for income taxes expense is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Company’s effective tax rate was -0.1% and -0.2% for the three months ended March 31, 2019 and 2018, respectively. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets and foreign withholding taxes. The Company may have experienced an ownership change under IRC Section 382 as a result of the common shares issued in connection with the March 2018 Purchase Agreement or in the June 2018 Offering. Such an ownership change may limit the Company’s ability to utilize its net operating loss carryforwards prior to expiration. Given the full valuation allowance, such a limitation would not impact the deferred tax asset balance as currently recorded. As of March 31, 2019, there have been no material changes to the Company’s uncertain tax positions.

Contingent Liability Related to

Contingent Liability Related to the Anawah Acquisition	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Contingent Liability Related to the Anawah Acquisition	11. Contingent Liability Related to the Anawah Acquisition On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs, thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. As of March 31, 2019, the Company continues to pursue three development programs using this technology and believes that the contingent liability is probable. As a result, $3.0 million remains on the Condensed Consolidated Balance Sheet as an other noncurrent liability.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Net Loss per Share	12. Net Loss per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As of March 31, 2019, all potentially dilutive common shares were determined to be anti-dilutive after evaluation. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Three Months Ended March 31, 2019 2018 Options to purchase common stock 535,243 252,554 Warrants to purchase common stock 2,821,144 382,645 Total 3,356,387 635,199

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related-Party Transactions	13. Related-Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and the JSF share common officers and directors. JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $12,000 and $29,000 as of March 31, 2019 and December 31, 2018, respectively, and are included in the Condensed Consolidated Balance Sheets as amounts due to related parties.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events The Company has reviewed and evaluated subsequent events through May 8, 2019, the date the condensed consolidated financial statements were available to be issued.

Description of Business and B_2

Description of Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Organization	Organization Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015. We are a consumer-driven, agricultural food ingredient company and proven leader in agricultural innovation to improve the quality and nutritional content of crops. We aim to create value across the agricultural production and supply chain beginning with enhanced crop productivity for farmers and ultimately delivering accelerated innovation in nutritional quality consumer foods. We use state of the art gene-editing technology and advanced breeding techniques to naturally enhance the nutritional quality of grains and oilseeds to address the rapidly evolving trends in consumer health and nutrition. In addition, we have developed high value crop productivity traits designed to enhance farm economics. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 5), which is jointly owned with Bioceres Crop Solutions Corp. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca ,
Reverse Stock Split	Reverse Stock Split In January 2018, the Company’s board of directors and its shareholders approved a reverse split of 1:20 on the Company’s issued and outstanding common stock which became effective on January 23, 2018. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented. The reverse stock split did not change the total number of authorized shares of common stock which remained at one hundred and fifty million shares.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and Verdeca in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities (“VIEs”). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. The Company evaluates its relationships with the VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Interim results are not necessarily indicative of results for any other interim period or for the full fiscal year. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K, filed with the SEC on April 1, 2019.
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern As of March 31, 2019, the Company had an accumulated deficit of $191.0 million, cash and cash equivalents of $10.4 million and short-term investments of $7.4 million. For the three months ended March 31, 2019 and the twelve months ended December 31, 2018, the Company had net losses of $12.6 and $13.5 million, and net cash used in operations of $4.0 million and $13.6 million, respectively. The Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through March 2020, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

SONOVA Gamma Linolenic Acid (_2

SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consist of the following (in thousands): March 31, 2019 December 31, 2018 Raw materials $ 41 $ 41 Finished goods 847 886 Inventories $ 888 $ 927

Investments and Fair Value of_2

Investments and Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Investments And Fair Value Of Financial Instruments [Abstract]
Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio	The following tables summarize the amortized cost and fair value of the available-for-sale investment securities portfolio at March 31, 2019 and December 31, 2018, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value March 31, 2019 Cash equivalents: Money market funds $ 6,283 $ — $ — $ 6,283 Corporate securities 599 — — 599 Commercial paper 3,044 — — 3,044 Short-term investments: Corporate securities 1,248 — — 1,248 Treasury Bills 997 — — 997 Commercial paper 5,110 — — 5,110 Total Assets at Fair Value $ 17,281 $ — $ — $ 17,281 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2018 Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper 1,345 — — 1,345 Short-term investments: Corporate Securities 656 — — 656 Treasury Bills 1,195 — — 1,195 Commercial paper 6,776 — — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 21,072 $ — $ — $ 21,072
Summary of Fair Value of Financial Assets	The following table sets forth the fair value of the Company’s financial assets as of March 31, 2019 and December 31, 2018: Fair Value Measurements at March 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,283 $ — $ — $ 6,283 Corporate securities — 599 — 599 Commercial paper — 3,044 — 3,044 Short-term investments: Corporate securities — 1,248 — 1,248 Treasury Bills 997 — — 997 Commercial paper — 5,110 — 5,110 Total Assets at Fair Value $ 7,280 $ 10,001 $ — $ 17,281 Fair Value Measurements at December 31, 2018 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper — 1,345 — 1,345 Short-term investments: Corporate Securities — 656 — 656 Treasury Bills 1,195 — — 1,195 Commercial paper — 6,776 — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 12,295 $ 8,777 $ — $ 21,072
Summary of Changes in Fair Value of Liabilities	The following table sets forth the establishment of these liabilities, as well as a summary of the changes in the fair value (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - Purchase Agreement Common Stock Warrant Liability - June Offering Total Balance as of December 31, 2018 $ 2,354 $ 2,729 $ 5,083 Change in fair value 3,970 4,525 8,495 Balance as of March 31, 2019 $ 6,324 $ 7,254 $ 13,578

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Lessee Disclosure [Abstract]
Schedule of Leases	Leases consisted of the following (in thousands): Leases Classification March 31, 2019 Assets Operating lease assets Right of use asset $ 2,193 Total leased assets $ 2,193 Liabilities Current - Operating Operating lease liability-current $ 574 Noncurrent - Operating Operating lease liability-noncurrent 1,771 Total leased liabilities $ 2,345 Lease Cost Classification For the Three Months Ended March 31, 2019 Operating lease cost SG&A and R&D Expenses $ 175 Short term lease cost(1) R&D Expenses 48 Sublease income(2) SG&A and R&D Expenses (15 ) Net lease cost $ 208 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a credit to lease expense. Lease Term and Discount Rate For the Three Months Ended March 31, 2019 Weighted-average remaining lease term (years) 2.6 Weighted-average discount rate 7%

Stock-Based Compensation and _2

Stock-Based Compensation and Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Under Stock Incentive Plans	A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2018 530,044 $ 35.53 $ — Options granted 7,500 3.57 Options exercised — — Options forfeited (1,287 ) 4.33 Options expired (1,014 ) $ 24.78 Outstanding — Balance at March 31, 2019 535,243 $ 35.13 $ 637 Vested and expected to vest — March 31, 2019 526,131 $ 35.47 $ 623 Exercisable —March 31, 2019 231,086 $ 60.40 $ 182
Weighted-Average Fair Value Assumption of Stock Option Awards	The fair value of stock option awards to executives and other service providers was estimated at the date of grant using the Black-Scholes Model with the following weighted-average assumption. There were 7,500 and 10,000 options granted during the three months ended March 31, 2019 and 2018, respectively. Three Months Ended March 31, 2019 2018 Expected term (years) 2.58 6.25 Expected volatility 133 % 100 % Risk-free interest rate 2.55 % 2.73 % Dividend yield — —

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Three Months Ended March 31, 2019 2018 Options to purchase common stock 535,243 252,554 Warrants to purchase common stock 2,821,144 382,645 Total 3,356,387 635,199

Description of Business and B_3

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Place of incorporation	Arizona
Year of incorporation	2002
Place of reincorporation	Delaware
Date of reincorporation	2015-03
Reverse split of issued and outstanding common stock	1:20
Accumulated deficit	$ (190,978)		$ (178,366)
Cash and cash equivalents	10,438	$ 20,418	11,998	$ 9,125
Short-term investments	7,355		9,825
Net losses	(12,612)	(10,615)	(13,480)
Net cash used in operations	$ (3,969)	$ (2,617)	$ (13,600)

SONOVA Gamma Linolenic Acid (_3

SONOVA Gamma Linolenic Acid ("GLA") Safflower Oil Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 41	$ 41
Finished goods	847	886
Inventories	$ 888	$ 927

Investments and Fair Value of_3

Investments and Fair Value of Financial Instruments - Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 17,281	$ 21,072
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	17,281	21,072
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,283	9,902
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	6,283	9,902
Cash Equivalents [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	3,044	1,345
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	3,044	1,345
Cash Equivalents [Member] | Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	599
Unrealized Gains	0
Unrealized Losses	0
Estimated Fair Value	599
Short-term Investments [Member] | Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	997	1,195
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	997	1,195
Short-term Investments [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	5,110	6,776
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	5,110	6,776
Short-term Investments [Member] | Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	1,248	656
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	$ 1,248	656
Short-term Investments [Member] | U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		1,198
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value		$ 1,198

Investments and Fair Value of_4

Investments and Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Jun. 14, 2018	Mar. 22, 2018
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Investment in continuous unrealized loss position for more than three months	$ 0
Unrealized gains and losses included in accumulated other comprehensive income or loss	0	$ 0
Other-than-temporary impairments associated with credit losses required to be recognized	$ 0
Common Stock Warrant Liability [Member] | Securities Purchase Agreement [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Shares of common stock issued				1,282,832
Common Stock Warrant Liability [Member] | Securities Purchase Agreement [Member] | Level 3 [Member] | June 2018 Offering [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Shares of common stock issued			1,461,962

Investments and Fair Value of_5

Investments and Fair Value of Financial Instruments - Summary of Fair Value of Financial Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Assets at Fair Value
Total Assets at Fair Value	$ 17,281	$ 21,072
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	6,283	9,902
Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	3,044	1,345
Short-term investments	5,110	6,776
Treasury Bills [Member]
Assets at Fair Value
Short-term investments	997
U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		1,198
Corporate Securities [Member]
Assets at Fair Value
Cash equivalents	599
Short-term investments	1,248	656
Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,195
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	7,280	12,295
Level 1 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	6,283	9,902
Level 1 [Member] | Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	0	0
Short-term investments	0	0
Level 1 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	997
Level 1 [Member] | U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		1,198
Level 1 [Member] | Corporate Securities [Member]
Assets at Fair Value
Cash equivalents	0
Short-term investments	0	0
Level 1 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,195
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	10,001	8,777
Level 2 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 2 [Member] | Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	3,044	1,345
Short-term investments	5,110	6,776
Level 2 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	0
Level 2 [Member] | U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		0
Level 2 [Member] | Corporate Securities [Member]
Assets at Fair Value
Cash equivalents	599
Short-term investments	1,248	656
Level 2 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments		0
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member] | Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	0	0
Short-term investments	0	0
Level 3 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	0
Level 3 [Member] | U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		0
Level 3 [Member] | Corporate Securities [Member]
Assets at Fair Value
Cash equivalents	0
Short-term investments	$ 0	0
Level 3 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments		$ 0

Investments and Fair Value of_6

Investments and Fair Value of Financial Instruments - Summary of Changes in Fair Value of Liabilities (Detail) - Level 3 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2018	$ 5,083
Change in fair value	8,495
Balance as of March 31, 2019	13,578
Common Stock Warrant Liability [Member] | Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2018	2,354
Change in fair value	3,970
Balance as of March 31, 2019	6,324
Common Stock Warrant Liability [Member] | June 2018 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2018	2,729
Change in fair value	4,525
Balance as of March 31, 2019	$ 7,254

Variable Interest Entity - Addi

Variable Interest Entity - Additional Information (Detail)	1 Months Ended	3 Months Ended
	Feb. 29, 2012Owner	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Variable Interest Entity [Line Items]
Direct expenses and allocated overhead amount | $		$ 243,000	$ 286,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of shareholders owning agricultural investment and development cooperative | Owner	300

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Leases - Additional Information

Leases - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2019
Lessee Lease Description [Line Items]
Existence of option to extend	true
Lease option to extend, description	Some leases (the warehouse, greenhouse and the Phoenix copier) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Assets
Operating lease assets	$ 2,193
Total leased assets	2,193
Liabilities
Current - Operating	574
Noncurrent - Operating	1,771
Total leased liabilities	2,345
Lease Cost
Net lease cost	$ 208
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	2 years 7 months 6 days
Weighted-average discount rate	7.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 175
Sublease income	(15)
R&D Expenses [Member]
Lease Cost
Short term lease cost	$ 48

Private Placement and Registere

Private Placement and Registered Direct Offering - Additional Information (Detail)	Jun. 11, 2018USD ($)$ / sharesshares	May 11, 2018USD ($)$ / sharesshares	Mar. 22, 2018$ / sharesshares	Mar. 19, 2018	Mar. 31, 2019USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	May 07, 2018USD ($)
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares					$ 18.15
Proceeds from issuance of private placement					$ 10,000,000
Offering costs					$ 226,000
Stock price | $ / shares					$ 32.52
Common stock no par value | $ / shares
Initial loss recognized on liabilities					$ 4,000,000
Liabilities marked to market value							$ 15,900,000
Additional loss/expense on liabilities							1,900,000
Offering cost, expense							$ 904,000
Issuance of placement agent warrants								$ 526,000
Proceeds from issuance initial public offering					50,000,000
Fair value of common stock warrants at inception					9,000,000
Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance of placement agent warrants					$ 526,000
Placement Agent [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares					15,038
Warrants issued, exercise price | $ / shares					$ 41.5625
Offering costs					$ 1,800,000
Warrant, exercisable term					5 years
Offering cost, expense					$ 1,800,000
June 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares					69,617
Warrants issued, exercise price | $ / shares					$ 12.568
Offering costs					$ 1,600,000
Aggregate agent fee paid					$ 980,000
Warrant, exercisable term					5 years
Offering cost, expense								721,000
Issuance of placement agent warrants					$ 427,000
Offering costs portion attributable to common stock					$ 912,000
Measurement Input, Price Volatility [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate					1
Measurement Input, Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate					0.0263
Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Stock price | $ / shares					$ 8.20
Black Scholes Merton Model [Member] | Measurement Input, Price Volatility [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate					1.08
Black Scholes Merton Model [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate					0.0283
Common Stock Adjustment Feature Liability [Member] | Monte Carlo Simulation Model [Member]
Class Of Warrant Or Right [Line Items]
Fair value of liabilities					$ 3,800,000
March 2018 Warrant Liability [Member] | Monte Carlo Simulation Model [Member]
Class Of Warrant Or Right [Line Items]
Fair value of liabilities					10,200,000
June 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value					7,300,000
Additional loss/expense on liabilities					4,500,000
Proceeds from issuance of common stock					5,000,000
Proceeds from issuance of common stock and warrants gross					14,000,000
March 2018 Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares			1,201,636
Warrant issued, shares of common stock called by warrant | shares			1,282,832
Warrants issued, exercise price | $ / shares			$ 10.7258
June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Offering costs					1,200,000
Proceeds from issuance of common stock and warrants gross					14,000,000
Proceeds from issuance of common stock and warrants net					12,800,000
March 2018 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Proceeds from issuance of private placement					8,700,000
Proceeds from offering costs of private placement, gross					10,000,000
Offering costs					1,300,000
Liabilities marked to market value									$ 8,400,000
Additional loss/expense on liabilities						$ 2,400,000
Reclassification of financing liabilities to stockholders equity						$ 8,400,000
March 2018 Private Placement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs					458,000
March 2018 Private Placement [Member] | Placement Agent [Member]
Class Of Warrant Or Right [Line Items]
Aggregate agent fee paid					850,000
March 2018 Private Placement [Member] | March 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value					6,300,000
Additional loss/expense on liabilities					$ 4,000,000
March 2018 Private Placement [Member] | March 2018 Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares			300,752
Warrant issued, shares of common stock called by warrant | shares			300,752
Warrants issued, exercise price | $ / shares			$ 45.75
Warrants expiration period				5 years
June 2018 Offering [Member]
Class Of Warrant Or Right [Line Items]
Issuance of placement agent warrants								$ 427,000
June 2018 Offering [Member] | June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares	1,392,345
Stock price | $ / shares	$ 9.93
Proceeds from issuance of common stock	$ 13,800,000
Offering closing period	Jun. 14, 2018
June 2018 Private Placement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares		1,392,345
Warrants issued, exercise price | $ / shares		$ 9.94
Warrants expiration period		5 years 6 months
Proceeds from offering costs of private placement, gross		$ 174,000
Class of warrant or right number of securities called by warrants or rights, per share | $ / shares		$ 0.125

Stock-Based Compensation and _3

Stock-Based Compensation and Warrants - Additional Information (Detail)	Mar. 28, 2019shares	May 20, 2015shares	May 14, 2015	Dec. 31, 2013$ / sharesshares	Jun. 30, 2019shares	Mar. 31, 2019USD ($)IncentivePlan$ / sharesshares	Sep. 30, 2018	Mar. 31, 2018USD ($)shares	Dec. 31, 2018shares	Jun. 30, 2014$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | IncentivePlan						2
Total number of options outstanding						535,243			530,044
Unrecognized compensation cost related to unvested stock-based compensation grants | $						$ 900,000
Weighted-average remaining recognition period						1 year 10 months 24 days
Options granted						7,500		10,000
Stock-based compensation | $						$ 422,000		$ 298,000
Number of warrant to purchase common stock issued						2,821,144
Warrants issued, exercise price | $ / shares						$ 18.15
March 2018 Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued						1,297,870
Warrants issued, exercise price | $ / shares						$ 10.7258
Series D Redeemable Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price | $ / shares										$ 363.20
Warrant issued, shares of common stock called by warrant										61,397
Number of warrants expired	1,759
Series D Redeemable Convertible Preferred Stock [Member] | Scenario Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants expired					59,638
Series D Redeemable Convertible Preferred Stock [Member] | Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price | $ / shares										$ 268.80
Warrant issued, shares of common stock called by warrant										1,674
Mahyco International [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued, exercise price | $ / shares				$ 330.40
Warrant issued, shares of common stock called by warrant				3,784
Warrant, expiration date				Dec. 11, 2018
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan						108,864
Percentage in payroll deductions to acquire shares of common stock			15.00%
Purchase plan offering period			6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage			85.00%
Issuance of common stock pursuant to employee stock purchase plan						9,353
Stock-based compensation | $						$ 4,300		$ 1,200
Purchase Agreement [Member] | June 2018 Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued						1,461,962
Purchase Agreement [Member] | June 2018 Offering [Member] | Purchase Price of $9.94 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued						1,392,345
Warrants issued, purchase price of warrants per share | $ / shares						$ 9.94
Purchase Agreement [Member] | June 2018 Offering [Member] | Exercise Price of $12.568 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrant to purchase common stock issued						69,617
Warrants issued, exercise price | $ / shares						$ 12.568
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan						The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan		154,387				538,953
Options vesting period		4 years					2 years
Common stock available for future grant						65,872
Total number of options outstanding						473,081
2015 Omnibus Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period		10 years
2015 Omnibus Equity Incentive Plan [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting percentage at end of one year		25.00%
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan		10,637
Total number of options outstanding						62,162

Stock-Based Compensation and _4

Stock-Based Compensation and Warrants - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	530,044
Shares Subject to Outstanding, Options granted	7,500	10,000
Shares Subject to Outstanding, Options Forfeited	(1,287)
Shares Subject to Outstanding, Options Expired	(1,014)
Shares Subject to Outstanding, Ending Balance	535,243
Shares Subject to Outstanding, Vested and expected to vest	526,131
Shares Subject to Outstanding, Exercisable	231,086
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 35.53
Weighted-Average Exercise Price Per Share, Options granted	3.57
Weighted-Average Exercise Price Per Share, Options forfeited	4.33
Weighted-Average Exercise Price Per Share, Options expired	24.78
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	35.13
Weighted Average Exercise Price Per Share, Vested and expected to vest	35.47
Weighted Average Exercise Price Per Share, Exercisable	$ 60.40
Aggregate Intrinsic Value, Outstanding Balance	$ 637
Aggregate Intrinsic Value, Vested and expected to vest	623
Aggregate Intrinsic Value, Exercisable	$ 182

Stock-Based Compensation and _5

Stock-Based Compensation and Warrants - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	2 years 6 months 29 days	6 years 3 months
Expected volatility	133.00%	100.00%
Risk-free interest rate	2.55%	2.73%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21.00%
Effective tax rate	(0.10%)	(0.20%)
Uncertain tax positions	$ 0

Contingent Liability Related _2

Contingent Liability Related to the Anawah Acquisition - Additional Information (Detail) $ in Thousands	Dec. 31, 2010USD ($)Program	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 15, 2005USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 3,000	$ 3,072
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability	$ 3,000			$ 5,000
Date of merger and reorganization		Jun. 15, 2005
Restructuring activities, description		As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs,
Number of development programs ceased | Program	3
Number of development programs | Program	6
Other noncurrent liability		$ 3,000

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	3,356,387	635,199
Option to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	535,243	252,554
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	2,821,144	382,645

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Royalty fees due	$ 12	$ 29
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due	$ 12	$ 29